
FDA Approves Novel Treatment for KRAS-Mutated Ovarian Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval of combination avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for the treatment of certain patients with KRAS-mutated recurrent low-grade serous ovarian …